FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Phase 1 Completed 37 enrolled Fate Therapeutics

Non-randomizedParallel-groupOpen-labelTreatment

Summary

FT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive immunity, and has the potential to overcome multiple mechanisms of immune checkpoint inhibitor (ICI) resistance. The preclinical data provide compelling evidence supporting the clinical investigation of FT500 as monotherapy and in combination with ICI in participants with advanced solid tumors.

Timeline

Start: 2019-02-15
Primary completion: 2022-11-15
Completion: 2022-11-15

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Atezolizumab	Monoclonal antibody	—	—
Subject	FT500	Cell therapy	—	—
Subject	Nivolumab	Monoclonal antibody	—	—
Subject	Pembrolizumab	Monoclonal antibody	—	—
Background	Cyclophosphamide	Other / unclassified	—	—
Background	Fludarabine	Small molecule	—	—
Background	IL-2	Protein / enzyme biologic	—	—

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Summary

Timeline

Drugs

Indications